A2FY34 Stock Overview
Operates as a medical education group in Brazil. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 5/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Afya Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$47.95 |
52 Week High | US$58.50 |
52 Week Low | US$41.00 |
Beta | 0.92 |
11 Month Change | -2.94% |
3 Month Change | -5.80% |
1 Year Change | -0.10% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 30.33% |
Recent News & Updates
Recent updates
Shareholder Returns
A2FY34 | BR Consumer Services | BR Market | |
---|---|---|---|
7D | -4.5% | 1.4% | 0.3% |
1Y | -0.1% | -41.7% | -1.7% |
Return vs Industry: A2FY34 exceeded the BR Consumer Services industry which returned -41.5% over the past year.
Return vs Market: A2FY34 exceeded the BR Market which returned -1.6% over the past year.
Price Volatility
A2FY34 volatility | |
---|---|
A2FY34 Average Weekly Movement | 13.9% |
Consumer Services Industry Average Movement | 7.5% |
Market Average Movement | 4.4% |
10% most volatile stocks in BR Market | 8.3% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: A2FY34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: A2FY34's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | Virgilio Deloy Gibbon | www.afya.com.br |
Afya Limited operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
Afya Limited Fundamentals Summary
A2FY34 fundamental statistics | |
---|---|
Market cap | R$8.54b |
Earnings (TTM) | R$579.64m |
Revenue (TTM) | R$3.19b |
14.7x
P/E Ratio2.7x
P/S RatioIs A2FY34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A2FY34 income statement (TTM) | |
---|---|
Revenue | R$3.19b |
Cost of Revenue | R$1.20b |
Gross Profit | R$1.99b |
Other Expenses | R$1.41b |
Earnings | R$579.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 6.41 |
Gross Margin | 62.39% |
Net Profit Margin | 18.20% |
Debt/Equity Ratio | 51.7% |
How did A2FY34 perform over the long term?
See historical performance and comparison